NewAmsterdam Pharma Company N.V. (NAMS) Operating income 2021–2025
NewAmsterdam Pharma Company N.V. (NAMS) annual operating income history from SEC filings — each fiscal year as reported.
-$225.7MFY2025 · since FY2021: -$35.0M → -$225.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$225.7M | -28.0% |
| FY2024 | -$176.3M | +3.6% |
| FY2023 | -$183.0M | -5043.9% |
| FY2022 | -$3.6M | +89.8% |
| FY2021 | -$35.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice